DE60122114D1 - Zusammensetzung zur verhinderung und/oder behandlung von gefässerkrankungen, bestehend aus propionyl-l-carnitin und coenzym q10 - Google Patents

Zusammensetzung zur verhinderung und/oder behandlung von gefässerkrankungen, bestehend aus propionyl-l-carnitin und coenzym q10

Info

Publication number
DE60122114D1
DE60122114D1 DE60122114T DE60122114T DE60122114D1 DE 60122114 D1 DE60122114 D1 DE 60122114D1 DE 60122114 T DE60122114 T DE 60122114T DE 60122114 T DE60122114 T DE 60122114T DE 60122114 D1 DE60122114 D1 DE 60122114D1
Authority
DE
Germany
Prior art keywords
carnitine
coenzyme
propionyl
prevention
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60122114T
Other languages
English (en)
Other versions
DE60122114T2 (de
Inventor
Claudio Cavazza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of DE60122114D1 publication Critical patent/DE60122114D1/de
Application granted granted Critical
Publication of DE60122114T2 publication Critical patent/DE60122114T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DE60122114T 2000-03-02 2001-02-20 Zusammensetzung zur verhinderung und/oder behandlung von gefässerkrankungen, bestehend aus propionyl-l-carnitin und coenzym q10 Expired - Lifetime DE60122114T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITRM000106 2000-03-02
IT2000RM000106A IT1316997B1 (it) 2000-03-02 2000-03-02 Composizione per la prevenzione e/o il trattamento di vasculopatie,che comprende propionil l-carnitina e coenzima q10.
PCT/IT2001/000081 WO2001064203A2 (en) 2000-03-02 2001-02-20 Composition for the prevention and/or treatment of vascular diseases, comprising propionyl l-carnitine and coenzyme q¿10?

Publications (2)

Publication Number Publication Date
DE60122114D1 true DE60122114D1 (de) 2006-09-21
DE60122114T2 DE60122114T2 (de) 2007-02-08

Family

ID=11454491

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60122114T Expired - Lifetime DE60122114T2 (de) 2000-03-02 2001-02-20 Zusammensetzung zur verhinderung und/oder behandlung von gefässerkrankungen, bestehend aus propionyl-l-carnitin und coenzym q10

Country Status (19)

Country Link
US (1) US6814972B2 (de)
EP (1) EP1263423B1 (de)
AR (1) AR027958A1 (de)
AT (1) ATE335473T1 (de)
AU (2) AU4103001A (de)
CA (1) CA2400959C (de)
CY (1) CY1106168T1 (de)
CZ (1) CZ20022758A3 (de)
DE (1) DE60122114T2 (de)
DK (1) DK1263423T3 (de)
ES (1) ES2269355T3 (de)
HU (1) HU229421B1 (de)
IT (1) IT1316997B1 (de)
MX (1) MXPA02008532A (de)
PL (1) PL207536B1 (de)
PT (1) PT1263423E (de)
SK (1) SK12402002A3 (de)
TN (1) TNSN01033A1 (de)
WO (1) WO2001064203A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE480231T1 (de) * 2001-05-10 2010-09-15 Kaneka Corp Zusammensetzungen für die transmukosale verabreichung mit coenzym q als wirkstoff
TW200304373A (en) * 2002-03-20 2003-10-01 Kanegafuchi Chemical Ind Percutaneous absorption promoters and compositions for treating athlete's foot
ES2587977T3 (es) 2009-05-01 2016-10-28 Celloxess Llc Tratamiento de la infertilidad masculina secundaria al estrés oxidativo de esperma
SG10201503032UA (en) * 2010-06-16 2015-06-29 Sigma Tau Ind Farmaceuti Acetyl-carnitine for use in a method for increasing neurogenesis in neural tissue

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1291113B1 (it) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
DE69814834T2 (de) * 1997-03-27 2004-04-08 Sole, Michael J., Toronto Ernährungszusammensetzung zur verbesserung der zellenenergie
US6232346B1 (en) * 1997-03-27 2001-05-15 Michael J. Sole Composition for improvement of cellular nutrition and mitochondrial energetics
IT1299197B1 (it) * 1998-06-30 2000-02-29 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante, antiproliferativa, energetica e atta a migliorare l'utilizzazione metabolica del glucosio.
IT1306130B1 (it) 1999-04-16 2001-05-30 Sigma Tau Healthscience Spa Composizione comprendente una carnitina e glutatione, atta adaumentare l'assorbimento del glutatione sinergizzandone gli effetti.
IT1306133B1 (it) * 1999-04-22 2001-05-30 Sigma Tau Healthscience Spa Composizione comprendente una carnitina ed un inositolfosfato, utilequale integratore dietetico o medicamento.
IT1317008B1 (it) 2000-04-04 2003-05-26 Sigma Tau Healthscience Spa Integratore alimentare energizzante sulla muscolatura scheletrica eprotettivo sull'apparato cardiovascolare.

Also Published As

Publication number Publication date
AU2001241030B8 (en) 2005-10-20
HU229421B1 (en) 2013-12-30
ES2269355T3 (es) 2007-04-01
CZ20022758A3 (cs) 2003-02-12
IT1316997B1 (it) 2003-05-26
HUP0204467A3 (en) 2006-07-28
US6814972B2 (en) 2004-11-09
CY1106168T1 (el) 2011-06-08
PT1263423E (pt) 2006-11-30
DK1263423T3 (da) 2006-12-11
ITRM20000106A0 (it) 2000-03-02
AU2001241030B2 (en) 2005-09-15
PL207536B1 (pl) 2010-12-31
CA2400959C (en) 2011-01-04
AU4103001A (en) 2001-09-12
EP1263423B1 (de) 2006-08-09
WO2001064203A2 (en) 2001-09-07
DE60122114T2 (de) 2007-02-08
EP1263423A2 (de) 2002-12-11
PL358178A1 (en) 2004-08-09
HUP0204467A2 (hu) 2003-06-28
TNSN01033A1 (fr) 2005-11-10
MXPA02008532A (es) 2003-02-12
SK12402002A3 (sk) 2003-02-04
WO2001064203A3 (en) 2002-03-28
AR027958A1 (es) 2003-04-16
CA2400959A1 (en) 2001-09-07
ATE335473T1 (de) 2006-09-15
US20030059418A1 (en) 2003-03-27
ITRM20000106A1 (it) 2001-09-02

Similar Documents

Publication Publication Date Title
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
DE60108080D1 (de) Aminopyrazolderivate zur behandlung von übergewicht und anderen gesundheitsstörungen
ATE265857T1 (de) Pharmazeutische oder diätetische zusammensetzung zur prävention oder behandlung von hyperoxalurie
ATE291438T1 (de) Pharmazeutische zusammensetzung zur behandlung von akutem schmerz, chronischem schmerz und/oder neuropathischem schmerz und migräne
DE60117046D1 (de) Kombination von fenofibrat und von coenzym q10 für die behandlung der endotheliaal missfunktion
DE60114580D1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
ATE281085T1 (de) Nahrungsergänzung zur behandlung von makula degeneration
DE69940131D1 (de) Mittel zur Behandlung von Erkrankungen der Speiseröhre
ATE390407T1 (de) Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
HK1091815A1 (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
ATE344253T1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE409176T1 (de) 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
DE60318839D1 (de) 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten
EP1635815A4 (de) Verfahren und verbindungen zur behandlung von gefässstenose
ATE362374T1 (de) Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust
DE60136826D1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
AU2002345255A1 (en) Composition comprising soy and use thereof in the prevention and/or treatment of various diseases
DE69920567D1 (de) Methode zur Verhütung des Körpergeruchs von alten Leute
DE60002226D1 (de) Zusammensetzung zur vorbeugung und/oder behandlung von kreislaufstörungen, enthaltend l-carnitin derivate und ginkgo biloba extrakte
DE69939075D1 (de) Pharmazeutische Zusammenstellung zur Vorbeugung und Behandlung von mit Zellkrankheiten des Augenhintergrundes zusammenhängenden Krankheiten
ATE335473T1 (de) Zusammensetzung zur verhinderung und/oder behandlung von gefässerkrankungen, bestehend aus propionyl-l-carnitin und coenzym q10
ATE347888T1 (de) Verwendung von aivlosin zur behandlung und prevention der lawsonia-infektionen in schweinen.
DE60223810D1 (de) Organische nitrat-derivate zur behandlung von atherosklerose und vaskulären erkrankungen
DE60128009D1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
ATE314064T1 (de) L-acetylcarnitin und l-propionylcarnitin zusammensetzung zur verhütung und behandlung von nierenstörungen und nierenenkrankheit

Legal Events

Date Code Title Description
8364 No opposition during term of opposition